Beriplex[®] Anticoagulation Reversal Quick Reference Guide

This interim guide is to support the use of BERIPLEX[®] in **Anticoagulation Reversal** where local guidelines have not yet been updated (awaiting national guideline by THANZ[#]). **Lower doses** are used in other settings including **cardiac surgery**, **trauma** & in patients with other thrombotic risk factors, seek specific expert guidance.

- > BERIPLEX[®] is a 4-factor prothrombin complex concentrate (PCC) with FII, FVII, FIX, FX (also contains heparin, proteins C & S). It replaces Prothrombinex[®]-VF (3-factor PCC). Ensure the prescription is written for the correct product available locally.
- > Indications, contraindications, precautions are consistent with Prothrombinex[®]-VF.
- > For Haematology advice consult on-call haematologist / critical bleeding consultant.

Rapid reversal of warfarin effect with Beriplex® 4-factor PCC & IV Vitamin K

Clinical setting	Interim [#] Guidance for Beriplex [®] in international units (IU)						
INR ≥ 1.5 with life-threatening (critical organ) bleeding, including intracranial bleeding	 Cease warfarin therapy and administer: vitamin K 5 –10 mg IV (0.3 mg/kg IV, max 10mg for children) and Beriplex 50 IU/kg IV based on weight capped at 100 kg. Consider dose <50 IU/kg if INR 1.5 – 1.9 or as per expert advice. FFP is not required for reversal of the warfarin effect as Beriplex contains all 4 vitamin K-dependent clotting factors. FFP may be required for associated major haemorrhage as directed by the local Massive Transfusion Protocol (MTP). 						
INR ≥ 2.0 with clinically significant bleeding (not life-threatening)	Cease warfarin therapy and administer: • vitamin K 5 –10 mg IV (0.3 mg/kg IV, max 10mg for children) • and Beriplex 25 – 50 IU/kg IV according to individual patient factors & INR, see below, based on weight capped at 100 kg.						
Pre-treatment INR	2.0 - 3.9	4.0 - 6.0	> 6.0				
Approx. dose IU/kg							

Vial size is 500 IU. Individualised dosing considerations include: type/degree of bleeding; nature, availability, timeliness of haemostatic interventions; thrombotic risks (indication for warfarin, others). Where PCC may be indicated in a non-bleeding patient (eg. urgent surgery; INR > 10 with high risk of bleeding), same dose of Beriplex can be considered as the Prothrombinex dose indicated for these settings in existing local warfarin reversal protocols (until updated) - consult haematologist.

35 IU/kg

25 IU/kg

Dosing of Beriplex[®] for DOAC reversal: when indicated, dose is 25 – 50 IU/kg (max. 5000 IU). Refer to local guidelines / MTP protocol, consult haematologist.

Administration of Beriplex®

body weight

- Reconstitution: 500 IU with 20 mL Water for Injection using Mix2Vial in box. Swirl do not shake. Do not mix with any other drugs, diluents, solutions or blood products.
- No blood should be in the infusion line: flush with 0.9% Normal Saline pre & post-dose. Do not pull back to check for blood (fibrin clot may develop).
- Infusion rates: not exceeding 3 IU/kg body weight/minute (0.12 mL/kg/min), up to a maximum of 210 IU/min (approx. 8 mL/min).

Weight-based adult infusion rates: calculate if weight 40 kg or less (see above):

> 40 – 65 kg	each 1000 IU (40 mL) over at least 8 mins (max. 5 mL/min or 300 mL/hr)
> 65 kg	each 1000 IU (40 mL) over at least 5 mins (max. 8 mL/min or 480 mL/hr)

Batch number must be documented: to ensure traceability for adverse events.

Developed by SA Critical Bleeding Advisory Group as an interim guide. Does not replace clinical judgment & expert guidance for individual patients. Refer to local protocols once updated. #Thrombosis & Haemostasis Society of Australia & New Zealand is updating their Warfarin reversal & DOAC Guidelines. Once completed, see: https://www.thanz.org.au/resources/thanz-guidelines

TP - L3 - 832 v 1.1, 29/7/2024 www.sahealth.sa.gov.au

 $\ensuremath{\textcircled{O}}$ Department for Health and Wellbeing, Government of South Australia. All rights reserved.



50 IU/kg



Beriplex[®] 4 Factor PCC - Warfarin Reversal Nomogram for use ONLY when 50 IU/kg dose is indicated

For reversal of Warfarin effect, INR ≥ 1.5 WITH life-threatening (critical organ) bleeding, including intracranial bleeding:

• Beriplex 50 IU/kg IV based on weight capped at 100 kg (consider a lower dose of <50 IU/kg if INR 1.5 – 1.9 or as per expert advice based on individual patient factors) & IV vitamin K.

Refer to Beriplex Quick Reference Guide for dosing in non life-threatening reversal of warfarin effect & dosing in NOAC reversal.

Beriplex 4 Factor PCC: 50 IU/kg dose. Use closest weight & round dose. Calculate dose & rate if weight <40 kg.										
Weight	50 IU/kg	50 IU/kg	No.	No. syringes	Volume to	Maximum	Maximum	Minimum time		
	Dose	Dose rounded	500 IU	40 mL per	be infused	rate	rate	for infusion of		
	(IU)	(IU)	vials	syringe	mL	mL/minute	mL/hour	dose (minutes)		
40 kg	2000	2000	4	2	80	5	300	16		
45 kg	2250	2500	5	2.5	100	5	300	20		
50 kg	2500	2500	5	2.5	100	6	360	16		
55 kg	2750	3000	6	3	120	6	360	20		
60 kg	3000	3000	6	3	120	7	420	17		
65 kg	3250	3500	7	3.5	140	7	420	20		
70 kg	3500	3500	7	3.5	140	8	480	17		
75 kg	3750	4000	8	4	160	8	480	20		
80 kg	4000	4000	8	4	160	8	480	20		
85 kg	4250	4500	9	4.5	180	8	480	22		
90 kg	4500	4500	9	4.5	180	8	480	22		
95 kg	4750	5000	10	5	200	8	480	25		
≥ 100 kg	5000	5000	10	5	200	8	480	25		

• Reconstitute with WFI using Mix2Vial in box. Swirl **do not** shake. Do not mix with any other drugs, diluents, solutions or blood products.

• No blood should be in the infusion line: flush with 0.9% Normal Saline pre & post-dose. Do not pull back to check for blood (fibrin clot may develop).

• Give according to the minimum infusion time / maximum rate above, as a slow push or via a syringe driver. Batch No. must be documented. Table uses weight-based rates from PI: rate not exceeding 3 IU/kg body weight/minute (0.12 mL/kg/min), to max. of 210 IU/min (approx. 8 mL/min). Vial size is 500 IU reconstituted with 20 mL WFI (25 IU/mL). PCC = Prothrombin Complex Concentrate. IU = International Units. WFI = Water for Injection.

Developed by SA Critical Bleeding Advisory Group as an interim guide. Does not replace clinical judgment & expert guidance for individual patients. Refer to local protocols once updated. #Thrombosis & Haemostasis Society of Australia & New Zealand is updating their Warfarin reversal & DOAC Guidelines. Once completed, see: https://www.thanz.org.au/resources/thanz-guidelines

